Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivaltinostat - CrystalGenomics

Next Previous
Drug Profile

Ivaltinostat - CrystalGenomics

Alternative Names: CG-200745; CG-745

Latest Information Update: 11 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CrystalGenomics
  • Class Amides; Antineoplastics; Naphthalenes; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cancer
  • Phase I/II Adenocarcinoma; Myelodysplastic syndromes; Pancreatic cancer

Most Recent Events

  • 18 Jan 2024 Efficacy data from a phase I/II trial in adenocarcinoma presented at the Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
  • 17 Nov 2023 CG Pharmaceuticals initiates phase II part of the phase Ib/II trial in Adenocarcinoma (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT05249101)
  • 15 Feb 2023 Machaon Biotherapeutics plans a phase I trial for Hematologic malignancy, Solid tumors and Fibrosis in Korea (NCT05716919)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top